Important safety information
Do not use VEOZAH if you:
- have cirrhosis.
- have severe kidney problems or kidney failure.
- are taking certain medicines called CYP1A2 inhibitors. Ask your healthcare provider if you are not sure.
Before you use VEOZAH, tell your healthcare provider about all of your medical conditions, including if you:
- have liver disease or problems.
- have kidney problems.
- have any medical conditions that may become worse while you are using VEOZAH.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VEOZAH may affect the way other medicines work, and other medicines may affect how VEOZAH works.
What are the possible side effects of VEOZAH?
VEOZAH can cause serious side effects, including:
- increased liver blood test values. Your healthcare provider will do a blood test to check your liver before you start taking VEOZAH. Your healthcare provider will also do this blood test at month 3, month 6, and month 9 after you start taking VEOZAH.
Call your healthcare provider right away if you have the following signs and symptoms of liver problems:
- nausea
- vomiting
- yellowing of the eyes or skin (jaundice)
- pain in the right upper stomach (abdomen)
The most common side effects of VEOZAH include:
- stomach (abdominal) pain
- diarrhea
- difficulty sleeping (insomnia)
- back pain
- hot flashes or hot flushes
These are not all the possible side effects of VEOZAH. Tell your healthcare provider if you have any side effect that bothers you or does not go away.
Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For more information, talk to your healthcare provider and see Patient Product Information for VEOZAH (fezolinetant).
VEOZAH® (fezolinetant) tablets
VEOZAH® is a prescription medicine used to reduce moderate to severe vasomotor symptoms due to menopause. VEOZAH® is not a hormone. Vasomotor symptoms are the feelings of warmth in the face, neck, and chest, or sudden intense feelings of heat and sweating; also known as hot flashes or night sweats.
VEOZAH® is a prescription medicine used to reduce moderate to severe vasomotor symptoms due to menopause. VEOZAH® is not a hormone. Vasomotor symptoms are the feelings of warmth in the face, neck, and chest, or sudden intense feelings of heat and sweating; also known as hot flashes or night sweats.
VEOZAH® was proven to reduce the number and severity of hot flashes and night sweats in as early as one week [based on clinical trials measuring efficacy at 4 and 12 weeks]. Individual results may vary. Talk with your healthcare provider about what this may mean for you.
VEOZAH® was proven to reduce the number and severity of hot flashes and night sweats in as early as one week [based on clinical trials measuring efficacy at 4 and 12 weeks]. Individual results may vary. Talk with your healthcare provider about what this may mean for you.
Neurokinin B (NKB) is a trigger for vasomotor symptoms. NKB is found in the temperature control center of your brain, the hypothalamus. When NKB binds to the receptior in the hypothalamus during menopause, it triggers hot flashes and night sweats. VEOZAH® works by blocking NKB from binding to the receptor.
Neurokinin B (NKB) is a trigger for vasomotor symptoms. NKB is found in the temperature control center of your brain, the hypothalamus. When NKB binds to the receptior in the hypothalamus during menopause, it triggers hot flashes and night sweats. VEOZAH® works by blocking NKB from binding to the receptor.
Activate your account
Match with a provider
Approve your care plan
Get your medications
Unlimited ongoing support
Explore more treatments
FAQs
Veozah is a non-hormonal FDA-approved prescription medication that reduces moderate to severe vasomotor symptoms (VMS) due to menopause. VMS—also known as hot flashes and night sweats—are the feelings of warmth in the face, neck, and chest, or sudden intense feelings of heat and sweating, commonly experienced during menopause.
Neurokinin B (NKB) is a chemical found in the hypothalamus, the temperature control center of your brain. When NKB binds to its receptor, it triggers hot flashes and night sweats. Veozah is designed to directly block NKB from binding to the receptor, thereby reducing the frequency and severity of hot flashes and night sweats due to menopause.
In clinical trials, Veozah was proven to reduce the number and severity of hot flashes and night sweats*, in as early as one week. Individual results may vary. Talk with your Evernow provider about what this may mean for you.
*Based on clinical studies measuring efficacy at 4 and 12 weeks.
Veozah is typically prescribed as a once-daily 45mg tablet, taken orally. It should be taken at the same time each day, with or without food. Take Veozah exactly as prescribed by your Evernow provider. Swallow the tablet whole with liquid. Do not cut, crush, or chew the tablet.
Veozah provides a non-hormonal alternative for the treatment of menopause vasomotor symptoms. To determine if Veozah is appropriate for you, consult with your Evernow provider. They will consider your specific symptoms, medical history, and overall health to help you make an informed decision and discuss potential risks and benefits.
Veozah, like any medication, can cause side effects. The most serious side effects include increased liver blood test values. Your Evernow provider will do a blood test to check your liver before you start taking Veozah. You will also be required to provide a blood test at month 3, month 6, and month 9 after you start taking Veozah. The most common side effects are: abdominal pain, diarrhea, insomnia, back pain, hot flush, and hepatic transaminase elevation. Stop using Veozah and message your provider right away if you experience signs and symptoms of liver injury (nausea, vomiting, yellowing of the eyes or skin, pain in the right upper abdomen).
Do not use Veozah if you have cirrhosis, severe kidney problems, or kidney failure. Do not take Veozah if you are taking certain medicines called CYP1A2 inhibitors. Ask your Evernow provider if you are not sure. Stop using Veozah and message your Evernow provider if follow-up evaluations of hepatic transaminase concentration is ≥ 2x ULN. Stop using when experiencing symptoms (such as nausea, vomiting, or yellowing of the skin or eyes) suggest liver injury.